GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

TSH Biopharm Corp 8432.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

61.40

+4.60%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About TSH Biopharm Corp

Its shares trade on Taipei Exchange under the ticker 8432.TWO. It has been listed since 16 June 2011. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.34bn and net income of TWD 139.3m. At that date it held total assets of TWD 1.95bn and shareholders' equity of TWD 1.44bn.

TSH Biopharm Corp., Ltd. engages in the provision of biotechnology services and sale of pharmaceuticals and chemical drugs. The company is headquartered in Taipei City, Taipei. The company went IPO on 2011-06-16. The firm primarily provides medicines for cardiovascular, including Amtrel, Rytmonorm, Licodin, Isormol and ISOPTIN SR; medicines for intestines and stomach, including MOPRIDE, Catilon, Gastro-Timelet and Ribarin, and medicines for central nervous, including Aleviatin, Lonine and Lacoxa SR. The firm distributes its products mainly in domestic markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
16 Jun 2011
Employees
57

Leadership

Pay as last reported

  • Mr. C. LinChairman of the Board, since 2020
  • Rongliang GaoChief Financial Officer
  • Ms. Sze-Yuan YangGeneral Manager
  • Shu-ping HuangHead of Finance
  • Mr. K.C. ChouDirector
  • Mr. Chia-Pin HsiaoDirector
  • Yongliang WuDirector
  • Ms. Ruixun ChenIndependent DirectorTWD 306,000
  • Yaobin HuangIndependent Director
  • Yunliang LaiIndependent Director
  • Xiuming WuIndependent Director
  • Deyu ZhouIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • TSH Biopharm Corp Ltd provides cardiovascular medicines like Amtrel and ISOPTIN SR in Taiwan.
  • The company offers intestinal and stomach medicines such as MOPRIDE and Catilon for domestic markets.
  • TSH Biopharm has a focused product range including central nervous system drugs like Aleviatin.

Weaknesses

  • TSH Biopharm operates primarily in the domestic market of Taiwan with limited international presence.
  • The company has only 57 employees, indicating a small operational scale.
  • TSH Biopharm's product portfolio is limited to specific therapeutic areas in Taiwan.

Opportunities

  • Expanding into international markets could leverage TSH Biopharm's pharmaceutical expertise.
  • Growing demand for cardiovascular medicines in Taiwan presents a market opportunity.
  • Increasing focus on central nervous system treatments could open new revenue streams.

Threats

  • Competition from larger pharmaceutical companies in Taiwan's domestic market.
  • Regulatory changes in Taiwan's pharmaceutical industry could impact operations.
  • Economic downturns in Taiwan might reduce healthcare spending on pharmaceuticals.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.